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Background: Higher dietary intake of potassium, calcium, and magnesium is protective
against ischemic strokes while also being associated with a decreased risk of all-cause
dementia. The effect of dietary iron intake on cerebral function is less clear but iron is also
implicated in Alzheimer neuropathology. The aim of this study was to investigate whether
dietary intake of these minerals was also associated with increased risk of mild cognitive
impairment (MCI, amnestic) and other mild cognitive disorders (MCD).
Methods: Associations between dietary mineral intake and risk of MCI/MCD were
assessed in cognitively healthy individuals (n=1406, 52% female, mean age 62.5 years)
living in the community, who were followed up over 8 years. Relative risk was assessed
with Cox hazard ratios (HRs) after controlling for health and socio-demographic covariates.
Results: Higher magnesium intake was associated with a reduced risk of developing
MCI/MCD (MCI: HR 0.07, 95% confidence interval (CI) 0.01–0.56, p=0.013; MCD: HR
0.47, 95% CI 0.22–0.99, p=0.046) in multivariate analyses. Higher intake of potassium
(MCI: HR 1.09, 95% CI 1.01–1.17, p=0.028; MCD: HR 1.05, 95% CI 0.99–1.10, p=0.107)
and iron (MCI: HR 1.54, 95% CI 1.03–2.29, p=0.034) was associated with an increased
risk of developing MCI/MCD.
Conclusion:These findings suggest that dietary intake of minerals known to be implicated
in biological processes associated with vascular and Alzheimer’s pathology may contribute
to disease progression earlier in the disease process and require further attention.
Keywords: magnesium, potassium, calcium, iron, dementia
INTRODUCTION
Worldwide dementia prevalence is projected to increase substan-
tially in the coming decades. In addition to lowering the quality
of life of sufferers and their family, this disease will put significant
strain on health and social services as well as incurring important
economic costs. As no cure or treatment for dementia is currently
available it is critical that, where possible, preventative actions be
implemented. Emerging evidence suggests that some dietary min-
erals (calcium, magnesium, potassium) are associated with lower
dementia risk. Since diet is highly modifiable and exerts its influ-
ence over the lifespan, it is imperative that we better understand
the associations between dementia and mineral intake, particu-
larly in the early stages of the disease where interventions are most
likely to be effective.
In a study of more than 1000 older individuals with a 17-year
follow-up Ozawa et al. (2012) showed that higher intake of cal-
cium, magnesium, and potassium was associated with a lower risk
of developing all-cause dementia, particularly vascular dementia.
In other studies, consistent protective effects of these minerals
were found in relation to hypertension and stroke (Iso et al.,
1999; Houston and Harper, 2008; Larsson et al., 2008). Higher
magnesium and calcium plasma levels were also found to be asso-
ciated with a lower risk of insulin resistance and type 2 diabetes
(Larsson and Wolk, 2007; Villegas et al., 2009; Wu et al., 2009),
which are known risk factors for dementia and poorer cogni-
tion (Cheng et al., 2012). Moreover, individuals suffering from
Alzheimer’s disease (AD) have been shown to have lower plasma
magnesium levels (Barbagallo et al., 2011). Together, this evidence
suggests a consistent link between intake of calcium, magnesium,
potassium, and future risk of cognitive decline.
Iron is another mineral thought to be implicated in Alzheimer
neuropathology. It has been found to co-localize with amyloid
plaques (Beauchemin and Kisilevsky, 1998; Dong et al., 2003) and
is thought to be implicated in the pathological process leading to
amyloid plaque aggregation (Roberts et al., 2012). Iron plasma lev-
els have also been found to be positively associated with cognitive
function in elderly individuals (Yavuz et al., 2012). These associa-
tions were detected even in the absence of anemia, where low iron
levels might lead to lower hemoglobin levels and possible cerebral
hypoxia, consequently other mechanisms might also be at play.
It is unclear, however, when associations between dietary min-
erals cognitive impairment become detectable in the prodro-
mal stages of dementia, the extent to which these associations
are due to interactions between different minerals, and whether
gender differences exist. In the present research, we investigate
associations between dietary mineral intake and the development
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of prospective mild cognitive disorders, including mild cognitive
impairment (MCI) while testing mineral–mineral and sex inter-
actions. A particular strength of this study is that we focus our
analyses on a large prospective cohort (n= 2551) of individuals
who were cognitively unimpaired at the first assessment, live in
the community and who are taking part in the PATH through life
project. The PATH project is a large longitudinal study of aging
and is unique in that it randomly samples individuals in their early
60s from the population, uses a narrow age-range design which
minimizes aging and cohort effects, and re-assesses participants
every 4 years over a very broad range of socio-demographic, health,
lifestyle, and neuropsychological measures. Based on research
reviewed above, we predicted that higher dietary intake of cal-
cium, magnesium, potassium, and iron would be associated with a
decreased risk of progressing from normal cognition to MCI and
other mild cognitive disorders over an 8-year follow-up.
MATERIALS AND METHODS
STUDY POPULATION
The design of the PATH through life study has been described
elsewhere (Kumar et al., 2005). Briefly, we recruited participants
who were residents of the city of Canberra and the adjacent town
of Queanbeyan, Australia, randomly through the electoral roll to
participate in a study interested in the risk and protective fac-
tors for common mental disorders, normal aging, and dementia.
Enrollment to vote is compulsory for Australian citizens. The Aus-
tralian National University Ethics Committee approved the study
and all participants gave written informed consent to be included
in this study and the participation rate was 58.3% (2551 out of
4376 participants invited). The present investigation focuses on
the middle-aged cohort, aged 60–64 years at wave 1 (2001–2002),
65–69 years at wave 2 (2005–2006), and 69–72 years at wave 3
(2009–2010). From 2551 participants recruited into the study, 455
were excluded because they either had a clinical diagnosis at wave
1 or did not complete the neuropsychological assessment at any
assessment, 556 individuals were excluded due to missing dietary
data at first assessment, 66 due to missing APOE data, 56 for stroke,
and a further 12 for epilepsy leaving 1406 participants for analysis
(Figure 1). Compared to 877 individuals who were not consid-
ered due to missing data, the selected participants did not differ
in age but had higher levels of education (13.98 vs. 13.34 years;
t (2549)=−5.277, p< 0.01) and were more likely to be women
(51.1 vs. 43.1%; Chi-square= 14.872, df= 1, p< 0.01).
SCREENING
At each wave, the same predetermined cutoff on a cognitive
screening battery was used to screen participants into a substudy
on MCDs and dementia. Participants from the full cohort were
selected for clinical assessment if they had any of the following:
(1) a Mini-Mental State Examination score≤25; (2) a score below
the fifth percentile on immediate or delayed recall of the first trial
of the California Verbal Learning Test (immediate or delayed score
of <4 and <2, respectively); (3) a score below the fifth percentile
on either of the following two tests: Symbol-Digit Modalities Test
(<33) or Purdue Pegboard with both hands (wave 1: <8; wave
2: <7) or reaction time (third set of 20 trials) (wave 1: >310 ms;
wave 2:>378 ms).
FIGURE 1 | Sample selection.
CLINICAL ASSESSMENT
The clinical assessment involved a Structured Clinical Assessment
for Dementia (available from us) by one of two physicians, a
neuropsychological assessment, and the Clinical Dementia Rating
Scale (Morris, 1993). Information was also gathered on med-
ical history related to cognitive function, duration of symptoms,
medical history from medical practitioners and family, current
treatment, and psychiatric history. Depression was assessed using
the self-administered Patient Health Questionnaire from the Pri-
mary Care Evaluation of Mental Disorders (PRIME-MD) (Spitzer
et al., 1999). Informant interviews were conducted when possi-
ble (57% of participants with MCI). Participants receiving any
clinical diagnosis were referred to their family doctor for lab-
oratory investigations. When necessary for diagnostic purposes
the research protocol included magnetic resonance imaging for
all consenting participants. The neuropsychological assessment
included frontal executive function [Trails A and B (Reitan, 1971),
Verbal Fluency (Lezak, 1995), and Clock Drawing (Sunderland
et al., 1989)], language [Boston Naming Short Form (Mack et al.,
1992)], constructional praxis from the Consortium to Establish a
Registry for AD battery (Morris et al., 1989), memory [Rey Audi-
tory Verbal Learning Test with verbal recall and recognition (Rey,
1941)] recall of constructional praxis for non-verbal memory, and
agnosia (Kertesz, 1983). Clinicians used clinical checklists, data
from the neuropsychological assessment, neuropsychiatric history,
and medical history to formulate consensus diagnoses. Criteria
for the following diagnoses were applied: MCI (Petersen et al.,
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1999; Winblad et al., 2004), age-associated memory impairment
(Crook et al., 1987), age-associated cognitive decline (Kral, 1962),
mild neurocognitive disorder (American Psychiatric Association,
1994), impairment on the Clinical Dementia Rating Scale (Roberts
et al., 2012), and other cognitive disorder (American Psychiatric
Association, 1994). Diagnostic and Statistical Manual of Mental
Disorders, fourth edition, criteria were used to assess dementia and
delirium (American Psychiatric Association, 1994). The Petersen
criteria for MCI were used at waves 1 and 2 (Petersen et al., 1999),
whereas the Winblad criteria (Winblad et al., 2004) were used at
wave 3. For all other categories, the same criteria were used for
all three waves and have been published by our group elsewhere
(Kumar et al., 2005). Important for this study, clinicians were blind
to the presence or lack of diagnosis obtained at waves 1 and 2.
DIETARY MEASURES
Dietary intake was measured using the Commonwealth Scientific
and Industrial Research Organization (CSIRO) Food Frequency
Questionnaire (FFQ) (Baghurst and Record, 1984), which consists
of questions on 215 food items as well as details about cooking
methods, serving sizes, comments about eating habits, and the
use of dietary supplements. Reported information in conjunction
with food composition tables for Australia was used to calculate
participants’ daily nutrient intake. This method has been shown to
have high repeatability and consistency with other dietary intake
measurement techniques and has demonstrated good reliability
compared with urinary and serum measures (Rohan et al., 1987;
Lazarus et al., 1995; Lassale et al., 2009). In the present study,
the daily intake of calcium (Ca), iron (Fe), magnesium (Mg), and
potassium (K) were considered. In order to account for the effect
of total caloric intake, the raw intake of minerals was normalized
to a daily caloric intake of 10 MJ. Effects of calcium, magnesium,
and potassium were evaluated per 100 mg increments while the
iron effect was investigated in 1 mg increments.
COVARIATES
Alcohol intake was assessed using the Alcohol Use Disorders Iden-
tification Test (AUDIT) and grouped into none/mild, moderate,
harmful/hazardous (Saunders et al., 1993). Present and past smok-
ing status was assessed by self-report. Body mass index (BMI) was
computed with the formula weight (kilogram)/height2 (square
meter), where height and weight were self-reported. Stroke and
diabetes were assessed by self-report (yes/no). Hypertension was
assessed based on blood pressure measures (systolic >140, dias-
tolic>90) or use of anti-hypertensive medication. Apolipoprotein
E e4 allele (APOE*E4) genotype was assessed by TaqMan assays
(Applied Biosystems) from DNA extracted from buccal swabs
(Cherbuin et al., 2008). Depressive symptomatology was assessed
with the Goldberg scale (Goldberg et al., 1988). Physical activity
was assessed based on the UK Whitehall II Study assessment and
coded into mild, moderate, and vigorous categories (Stafford et al.,
1998).
STATISTICAL ANALYSIS
Descriptive analyses were conducted using Chi-square for categor-
ical data and t -tests to compare groups on continuous variables.
We calculated Cox proportional hazards models to produce a risk
measure in multivariate analyses with MCI or MCD as the dichoto-
mous outcomes and intake of minerals as predictors (Model 1) and
while controlling for age, sex, education,APOE*E4 genotype, BMI,
physical activity, stroke, diabetes, hypertension, depressive symp-
tomatology, alcohol intake, and smoking (Model 2). The time to
event variable was time of diet assessment to first MCI or MCD
diagnosis at study assessment. Subjects who were assessed and did
develop any MCD were censored at the time of their last follow-
up. Quadratic effects were estimated for the associations between
the minerals and diagnostic categories to investigate non-linear
relationships. Sex-mineral interactions and interactions between
significant minerals were tested. Significance is reported at α 0.05
and 0.01 levels.
RESULTS
Table 1 presents the demographic and neuropsychological charac-
teristics of the study groups (Normal, MCI, and MCD) as well as
Table 1 | Demographic, clinical, dietary, and genetic characteristics of
normal, MCI and MCD sub-samples.
Normal (n =1354) MCI (n =27) MCD (n =52)
Females, n (%) 700 (51.70) 10 (37.00) 22 (42.30)
Age wave 1, years
(SD)
62.54 (1.53) 62.37 (1.80) 62.50 (1.60)
Education years (SD) 14.15 (2.57) 13.06** (1.91) 13.08** (2.21)
Caucasian, n (%) 1321 (97.60) 26 (96.30) 51 (98.10)
MMSE
At wave 1 (SD) 29.43 (0.85) 28.41** (1.22) 28.63** (1.12)
At wave 2 (SD) 29.41 (0.86) 28.27** (1.19) 28.45** (1.24)
At wave 3 (SD) 29.32 (0.97) 27.81** (1.65) 27.74 (1.93)
BMI kg/m2 (SD) 26.60 (4.99) 27.27 (4.97) 27.64** (6.36)
ACTIVITY LEVEL, n (%)
Low 663 (49.00) 12 (44.40) 29 (55.80)
Moderate 516 (38.10) 13 (48.10) 19 (36.50)
High 175 (12.90) 2 (7.40) 4 (7.70)
Diabetes, n (%) 72 (5.30) 6** (22.20) 10** (18.30)
Hypertension, n (%) 831 (61.90) 16 (61.50) 31 (60.80)
ALCOHOL, n (%)
Abstainers 351 (25.90) 11 (30.70) 16 (30.80)
Moderate 917 (67.70) 16 (59.20) 40 (69.30)
Harmful 86 (6.40) 0 (0.00) 0 (0.00)
Caloric intake
MJ (SD)
8.54 (2.27) 9.13 (2.62) 8.77 (2.36)
Present and past
smokers, n (%)
633 (46.8) 12 (44.40) 26 (50.00)
APOE*E4 carrier,
n (%)
370 (27.30) 5 (18.50) 14 (28.80)
DIETARY MINERAL INTAKE PER 10MJ
Calcium, g (SD) 1.21 (0.38) 1.26 (0.42) 1.23 (0.37)
Iron, mg (SD) 17.78 (3.96) 17.39 (4.32) 17.35 (3.82)
Magnesium, mg (SD) 434 (78) 422 (82) 427 (78)
Potassium, g (SD) 4.91 (1.00) 5.03 (1.08) 4.89 (1.12)
Differences between clinical and normal groups: significant at *0.05, **0.01.
MMSE, mini-mental state examination; BMI, body mass index.
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Table 2 | Dietary predictors of transition from normal aging to MCI or MCD.
Predictors MCI MCD
Model 1 Model 2 Model 1 Model 2
HR (95% CI) P HR (95% CI) P HR (95% CI) P HR (95% CI) P
Calcium 1.02 (0.99–1.01) 0.767 1.01 (0.89–1.15) 0.866 1.05 (0.96–1.14) 0.311 1.05 (0.96–1.14) 0.309
Iron 1.50 (1.07–2.10) 0.019 1.54 (1.03–2.29) 0.034 1.05 (0.95–1.16) 0.309 1.10 (0.87–1.37) 0.418
Magnesium 0.08 (0.02–0.47) 0.005 0.07 (0.01–0.56) 0.013 0.45 (0.21–0.96) 0.039 0.47 (0.22–0.99) 0.046
Potassium 1.09 (1.02–1.17) 0.016 1.09 (1.01–1.17) 0.028 1.05 (0.99–1.11) 0.070 1.05 (0.99–1.10) 0.107
INTERACTIONS
Sex×magnesium 2.87 (1.02–7.97) 0.046 3.41 (0.92–12.65) 0.068
Sex× iron 0.73 (0.56–0.94) 0.016 0.71 (0.52–0.97) 0.031 0.97 (0.93–0.99) 0.045
Model 1: unadjusted; Model 2: adjusted for age, sex, education, body mass index, activity level, diabetes, hypertension, depression, smoking, alcohol intake.
MCI, mild cognitive impairment; MCD, mild cognitive disorder; HR, hazard ratio; CI, confidence interval.
their daily mineral intake. We identified 27 MCI and 52 MCD indi-
viduals from the 1406 participants, who did not have a diagnosis
at wave 1 and who were included in the study.
Average mineral intake in this cohort is generally consistent
with advice from the National Health and Medical Research Coun-
cil (NHMRC) of Australia, which recommends a daily intake of
420 mg of magnesium, 1000 mg of calcium, and 8 mg for iron in
men and 420 mg of magnesium, 1000 mg of calcium, and 8 mg
for iron in women in their 60s. However, iron intake at more than
18 mg in this sample is substantially higher than the recommended
value. There is no NHMRC recommendation for potassium but
the reported daily average intake is 3800 mg for men and 2800 mg
for women and consistent with that found in this study.
Results from the unadjusted multivariate Cox regression analy-
ses predicting transition from normal cognition to MCI and MCD
(Model 1) and after controlling for age, sex, education, BMI,
physical activity, diabetes, hypertension, depression, smoking, and
alcohol intake category (Model 2) are presented in Table 2 and
show that intake of magnesium was associated with a decreased
risk of MCI while potassium and iron were associated with an
increased risk. None of the mineral by mineral interactions or qua-
dratic effects reached significance. However, for MCI significant
sex interactions were detected for magnesium and iron.
Follow-up analyses demonstrated that higher magnesium
intake was associated with a decreased MCI risk in males (HR
0.14, 95% CI 0.03–0.60, p= 0.008) but not in females (HR 1.36,
95% CI 0.26–7.08, p= 0.714) and suggested (trends) that higher
iron intake was associated with a decreased risk of MCI in females
(HR 0.81, 95% CI 0.61–1.07, p= 0.144) and an increased risk in
males (HR 1.08, 95% CI 0.94–1.18, p= 0.287). Visual representa-
tions of the estimated risk for each mineral relative to NHMRC
recommended values and upper limits are presented in Figure 2.
ADDITIONAL ANALYSES
To shed light on the sex interactions detected, magnesium and iron
intake per 10 MJ was contrasted between males and females. For
magnesium, male (mean 415 mg, SD 76) was lower than female
(mean 451 mg, SD 77) intake in cognitively intact individuals
(t =−8.55, p> 0.001) but even more so in MCI participants
(Males: mean 403 mg, SD 81; Females: mean 468 g, SD 55;
t =−2.25, p< 0.05). For iron, male (mean 17.11 mg, SD 3.80)
was lower than female (mean 18.38 mg, SD 4.00) intake in cog-
nitively intact individuals (t =−6.02, p> 0.001) but not in MCI
participants (Males: mean 17.82, SD 4.99; Females: mean 16.66 SD
2.96; t = 0.666, ns).
In addition, as in the present analyses mineral intake was con-
sidered as a density per 10 MJ to provide an easily understandable
metric and since this approach can potentially confound the effects
of the minerals investigated with that of caloric intake, further
analyses were conducted to exclude this possibility. Firstly, analy-
ses were repeated using caloric intake as an additional covariate
and secondly using the approach suggested by Willett et al. (1997)
the variance in caloric intake shared with mineral intake measures
was partialed out. This was done by regressing the mineral intake
on caloric intake and saving the residuals. For each mineral the
mean cohort intake per 10 MJ was added to the residuals. This
does not affect the statistical effects but “standardizes” nutrient
intake to an average typical for a known caloric intake. In both
sets of analyses (Supplementary Tables 1 and 2), results followed a
similar and consistent pattern suggesting caloric intake is not the
underlying factor that produced the present results.
DISCUSSION
The most significant findings emerging from this study were (1)
that dietary intake of minerals implicated in AD pathology and
risk of developing AD (iron, magnesium, potassium) were found
to be associated with risk of progression from normal aging to MCI
and MCD and (2) that for magnesium and iron these associations
differed between sexes.
As predicted, higher intake of magnesium was associated with
a decreased risk of MCI/MCD. This is consistent with previous
research but nevertheless interesting since here it relates to mild
cognitive disorders thus suggesting a continuum of effects span-
ning cognitive decline in aging, MCDs, and dementia. However,
this effect appeared to be only present in males who had over-
all a lower intake of magnesium than females but even more
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FIGURE 2 | Risk of developing MCI associated with minerals of
interest in cognitively healthy individuals (blue, based on observed
group mean intake relative to recommended intake from the
NHMRC) compared to the risk associated with the NHMRC upper
limit (pink) or were no upper limit is available the observed value
in the present sample associated with greatest risk. A positive value
represents a percent increased risk and a negative value a percent
decreased risk.
so in the MCI/MCD groups. These findings are particularly
interesting in light of recent research in animal models of AD.
Li et al. (2013) found that rats whose diet was complemented
with magnesium (in drinking water) suffered less synaptic loss
in the hippocampus, developed less amyloid plaques, and demon-
strated preserved learning and memory capacities compared to
controls. The authors also noted that long-term magnesium
supplementation increased CSF concentration by only 15% while
total brain concentration increased by 30%. This suggests that
small increases in magnesium intake may lead to substantial brain
changes particularly since additional investigation showed that
increasing intra-cellular magnesium by 15% led to a 50% increase
in synaptic density. These findings are also consistent with a post-
mortem study, which found that the magnesium content in the
hippocampus of AD patients was reduced by 18% compared to
controls (Andrasi et al., 2005).
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Surprisingly, no effect of calcium and an opposite effect of
potassium were found. In relation to potassium, it may be that
the risk associated with its intake is not linear and that it is a pro-
tective factor earlier in the disease process, as shown by Ozawa
et al. (2012) over a 17-year follow-up – likely through positive
effects on cardio-vascular function – and that it becomes a risk
factor closer to clinical diagnosis. This hypothesis is consistent
with recent findings showing higher potassium concentrations in
brains of individuals with AD compared to controls (Vitvitsky
et al., 2012). Similarly, calcium may be protective earlier in life
but may be ineffective in altering existing cardio-vascular pathol-
ogy and thus may not alter cerebral health and function in older
individuals.
An effect of dietary iron was detected suggesting the presence
of an overall increased risk in association with higher iron intake.
In addition, a significant sex interaction was present and although
follow-up analyses only provided trends, probably due to smaller
cell sizes, they hinted at a protective effect of iron in females and
an increased risk in males. The sex difference does not appear to be
due to variations in dietary concentrations as females had higher
iron intakes than males. This gender effect may therefore be due
to physiological differences or to a combination of factors such as
overall diet, physical fitness, and general health.
While an investigation or detailed discussion of specific foods
associated with mineral intake is beyond the scope of this study, it
is useful to note that the foods with the highest content in mag-
nesium include green vegetables, nuts and seeds, and unrefined
grains all of which have been shown to have health benefits and
specifically in relation to their cardio-vascular and anti-oxidant
effects as well as their low GI nature (Ness and Powles, 1997; Kang
et al., 2005; Dauchet et al., 2006; Brand-Miller and Buyken, 2012;
Martinez-Lapiscina et al., 2013). Consequently, it is possible that
the associations detected between magnesium and risk of cognitive
decline are at least in part attributable to other qualities of foods
that contain it, particularly since diets rich in vegetables and fish
have been shown to be associated with a lower risk of dementia
(Solfrizzi et al., 2011; Otaegui-Arrazola et al., 2014). Magnesium
is also necessary for efficient calcium uptake. Potassium-rich food
include pumpkin, potatoes, bananas, oily fish, yogurt, and dried
fruit, which are generally thought to be healthy foods, therefore the
negative effect detected in the present study may relate to the way
in which some of these foods are prepared (e.g., chips). This ques-
tion requires further investigation in future research. Finally, foods
high in iron include red meat, oily fish, wholegrain cereal, and dark
green vegetables. Gender differences associated with iron intake
may be due to physiological differences between men and women
but could also be driven by different dietary patterns, which can
have opposite effects. For example, low iron levels in women are
associated with a higher risk of depression which is a risk fac-
tor for dementia. In contrast, high intake of red meat, which is
rich in iron, is associated with a higher risk of cardio-vascular
disease.
Although, based on current evidence it is reasonable to hypoth-
esize that mineral intake may lead to cognitive decline, reverse
causation is also possible whereby those in the pre-clinical stages
of dementia alter their diet. This explanation seems less likely here
as all individuals included in the study were in their early 60s,
cognitively healthy at baseline, and because the outcome measure
was not dementia itself but mild cognitive disorders.
This study had a number of limitations but also significant
strengths. The cohort surveyed may not generalize to other pop-
ulations and due to the correlational nature of this research our
findings may be accounted for by other factors, which covary with
dietary intake, including other nutrients that co-occur in foods
rich in the minerals examined. To decrease this possibility, we
took care in controlling for important covariates and particularly
BMI and total caloric intake. Since dietary intake was assessed by
self-report mineral intake measures are likely to be somewhat less
reliable than those of more objective methods although a validated
FFQ was used. However, this should have led to decreased statis-
tical power, which makes the strong findings demonstrated in this
research all the more notable. It should also be noted that intake of
nutrients is not equivalent to the dose absorbed as different indi-
viduals have different absorption rates under different conditions.
Unfortunately, blood measures were not available to explore how
dietary intake relates to plasma concentrations and this question
should be further investigated in future studies. Despite these limi-
tations, this study’s strengths included a large cohort of individuals
selected randomly from the electoral roll, followed longitudinally
and assessed for cognitive impairment using a clinical interview
and validated criteria.
In summary, this investigation provides new evidence link-
ing increased magnesium intake with decreased risk of cogni-
tive impairment. Importantly, these findings were detected ear-
lier in the disease process than previous studies, which focused
on dementia and therefore are more consistent with exposure
to longer-term diet quality rather than change in dietary intake
shortly before the onset of dementia. This study also produced
unexpected results, which may be due to the heterogeneous nature
of the MCI syndrome, regional difference in diet quality, or non-
linear effect along the disease continuum, which will need to be
clarified in future research.
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